Tirzepatide 60mg Research Peptide Vial

Tirzepatide — Dual GIP/GLP-1 Receptor Agonist for Metabolic Research

Tirzepatide is a synthetic dual incretin receptor agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Extensively studied in preclinical and clinical research, it is investigated for its effects on glycemic control, body weight reduction, and multiple cardiometabolic parameters in models of obesity and type 2 diabetes.

What It Is

• Class: Dual GIP/GLP-1 receptor agonist (incretin mimetic)

• Concept: Simultaneously engages both incretin pathways to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and modulate appetite and energy balance.

• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Incretin & Islet Biology

• GIP receptor activation: Potentiates glucose-dependent insulin secretion and supports β-cell function in metabolic models.

• GLP-1 receptor activation: Enhances insulin secretion, reduces inappropriate glucagon release, and slows gastric emptying.

• Dual agonism: Explored for synergistic benefits compared to single-receptor incretin agonists.

Body Weight & Metabolic Effects

• Acts on central appetite and satiety pathways, leading to reduced caloric intake in research settings.

• Associated with reductions in body weight, fat mass, and waist circumference in obesity models.

• Investigated for favorable effects on lipids, liver fat, inflammatory markers, and overall cardiometabolic health.

Selected Research Highlights

• Type 2 Diabetes: Demonstrated robust reductions in HbA1c, fasting glucose, and postprandial glucose excursions, often outperforming certain single incretin agonists.

• Obesity & Weight Management: Produced substantial weight loss and improvements in body composition in obesity cohorts.

• Liver & NAFLD/NASH: Evaluated for reductions in liver fat content, transaminases, and other markers of nonalcoholic fatty liver disease.

• Cardiometabolic Parameters: Studied for beneficial effects on blood pressure, lipid profiles, and additional cardiovascular risk factors in high-risk populations.

Chemical & Handling Information

• Type: Synthetic dual incretin receptor agonist

• Targets: GIP receptor and GLP-1 receptor

• Appearance: White to off-white lyophilized powder

Specifications

• Peptide: Tirzepatide

• Amount: 60 mg per vial

• Form: Lyophilized powder

• Purity: ≥99% (HPLC) – Certificate of Analysis available per lot

• Packaging: Sealed, sterile vials suitable for laboratory use

Storage & Stability

• Store lyophilized vials in a cool, dry place protected from light.

• Refrigeration or freezing of the lyophilized peptide is recommended for long-term stability per laboratory SOPs.

• After reconstitution: Refrigerate at 2–8 °C for short-term use.

• Long-term storage: Aliquot and freeze at –20 °C or below. Avoid repeated freeze-thaw cycles.